Eterna Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $12.85 million. The enterprise value is $46.28 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 51.37 million shares outstanding. The number of shares has increased by 11.09% in one year.
| Current Share Class | 51.37M |
| Shares Outstanding | 51.37M |
| Shares Change (YoY) | +11.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 48.62% |
| Owned by Institutions (%) | 10.02% |
| Float | 21.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.26 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 77.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48
| Current Ratio | 0.48 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -42.35% |
| Return on Capital (ROIC) | -71.61% |
| Revenue Per Employee | $74,750 |
| Profits Per Employee | -$5.62M |
| Employee Count | 8 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ERNA has paid $15,000 in taxes.
| Income Tax | 15,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.55% in the last 52 weeks. The beta is 7.21, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 7.21 |
| 52-Week Price Change | -83.55% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 22.59 |
| Average Volume (20 Days) | 2,078,878 |
Short Selling Information
The latest short interest is 115,021, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 115,021 |
| Short Previous Month | 47,428 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
In the last 12 months, ERNA had revenue of $598,000 and -$44.95 million in losses. Loss per share was -$8.31.
| Revenue | 598,000 |
| Gross Profit | 436,000 |
| Operating Income | -20.32M |
| Pretax Income | -22.90M |
| Net Income | -44.95M |
| EBITDA | -20.18M |
| EBIT | -20.32M |
| Loss Per Share | -$8.31 |
Full Income StatementBalance Sheet
The company has $4.26 million in cash and $37.70 million in debt, giving a net cash position of -$33.43 million or -$0.65 per share.
| Cash & Cash Equivalents | 4.26M |
| Total Debt | 37.70M |
| Net Cash | -33.43M |
| Net Cash Per Share | -$0.65 |
| Equity (Book Value) | -45.39M |
| Book Value Per Share | -8.39 |
| Working Capital | -5.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.95 million and capital expenditures -$388,000, giving a free cash flow of -$17.34 million.
| Operating Cash Flow | -16.95M |
| Capital Expenditures | -388,000 |
| Free Cash Flow | -17.34M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
| Gross Margin | 72.91% |
| Operating Margin | -3,397.66% |
| Pretax Margin | -7,511.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |